Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as volociximab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Volociximab may also stop the
growth of non-small cell lung cancer by blocking blood flow to the tumor. Erlotinib may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving
volociximab together with erlotinib may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving volociximab together with erlotinib
works in treating patients with stage III or stage IV non-small cell lung cancer.